Ophthalmology in China

Previous Articles     Next Articles

Comparison of two different regimens of intravitreal ranibizumab therapy for macular edema secondary to central retinal vein occlusion

ZHAO Xu-li, ZHANG Di, YANG Guang, HUANG Ge   

  1. Department of Ophthalmology, Chengdu Second People’S Hospital, Chengdu 610017, China
  • Received:2018-04-23 Online:2019-03-25 Published:2019-03-28
  • Contact: ZHAO Xu-li, Email: lilyzhao999@163.com


Objective To compare the efficacy of two different regimens of ranibizumab for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). The two different regimens were 1 initial injection+pro re nata (PRN) administration and 3 successive monthly initial injections + PRN.  Design Non-random case-control study. Participants 49 cases (49 eyes) who were diagnosed with macular edema secondary to CRVO in Chengdu second people's Hospital from December 2015 to February 2017. The average age was 60.5±12.1 years old.  Method All patients were treated with intravitreal injection of ranibizumab 0.5 mg. According to the different injection regimens, patients were divided into 2 groups: 29 eyes received 1 initial injection (1+PRN group) and 20 eyes received 3 monthly loading injections (3+PRN group). The patients with peripheral retinal non-perfusion area were additionally given with peripheral retinal laser photocoagulation. The patients were followed monthly for 1 year. The number of injections was counted. The changes of BCVA and CFT were compared between the two groups. Main Outcome Measures The number of injections, BCVA and CFT. Results The number of injections in the 1+PRN group was significantly lower than 3+PRN group (4.1±2.8 versus 5.9±2.1, P=0.02) during the 12-month follow-up period. The BCVA (logMAR) increased from baseline 0.481±0.258 to 0.344±0.376 in 1+PRN group and from baseline 0.467±0.343 to 0.325±0.315 in 3+PRN group. At month 12, the CFT decreased from baseline 599.3±191.3 μm to 318.8±124.8 μm in 1+PRN group and from 644.4±237.4 μm to 335.5±153.6μm in 3+PRN group respectively. There was no significant difference in BCVA and CFT between the two groups at both baseline and final visit.  Conclusions Using ranibizumab for macular edema secondary to CRVO, 1+PRN regimen achieved similar 12-month outcomes to 3+PRN regimen with fewer injections. (Ophthalmol CHN, 2019, 28: 111-114)

Key words: angiogenesis inhibitors;ranibizumab;retinal vein occlusion/complications, macular edema/drug therapy